Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor

Matthew L. Springer, Gonzalo Hortelano, Donna M. Bouley, Jason Wong, Peggy E. Kraft, Helen M. Blau

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: We previously demonstrated that intramuscular implantation of primary myoblasts engineered to express vascular endothelial growth factor (VEGF) constitutively resulted in hemangioma formation and the appearance of VEGF in the circulation. To investigate the potential for using allogeneic myoblasts and the effects of delivery of VEGF-expressing myoblasts to non-muscle sites, we have enclosed them in microcapsules that protect allogeneic cells from rejection, yet allow the secretion of proteins produced by the cells. Methods: Encapsulated mouse primary myoblasts that constitutively expressed murine VEGF164, or encapsulated negative control cells, were implanted either subcutaneously or intraperitoneally into mice. Results: Upon subcutaneous implantation, capsules containing VEGF-expressing myoblasts gave rise to large tissue masses at the implantation site that continued to grow and were composed primarily of endothelial and smooth muscle cells directly surrounding the capsules, and macrophages and capillaries further away from the capsules. Similarly, when injected intraperitoneally, VEGF-producing capsules caused significant localized inflammation and angiogenesis within the peritoneum, and ultimately led to fatal intraperitoneal hemorrhage. Notably, however, VEGF was not detected in the plasma of any mice. Conclusions: We conclude that encapsulated primary myoblasts persist and continue to secrete VEGF subcutaneously and intraperitoneally, but that the heparin-binding isoform VEGF164 exerts localized effects at the site of production. VEGF secreted from the capsules attracts endothelial and smooth muscle cells in a macrophage-independent manner. These results, along with our previous results, show that the mode and site of delivery of the same factor by the same engineered myoblasts can lead to markedly different outcomes. Moreover, the results confirm that constitutive delivery of high levels of VEGF is not desirable. In contrast, regulatable expression may lead to efficacious, safe, and localized VEGF delivery by encapsulated allogeneic primary myoblasts that can serve as universal donors.

Original languageEnglish
Pages (from-to)279-288
Number of pages10
JournalJournal of Gene Medicine
Volume2
Issue number4
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Myoblasts
Vascular Endothelial Growth Factor A
Capsules
Smooth Muscle Myocytes
Macrophages
Peritoneum
Hemangioma
Heparin
Protein Isoforms
Hemorrhage
Inflammation

Keywords

  • Angiogenesis
  • Encapsulation
  • Gene therapy
  • Myoblasts
  • VEGF

ASJC Scopus subject areas

  • Genetics

Cite this

Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor. / Springer, Matthew L.; Hortelano, Gonzalo; Bouley, Donna M.; Wong, Jason; Kraft, Peggy E.; Blau, Helen M.

In: Journal of Gene Medicine, Vol. 2, No. 4, 2000, p. 279-288.

Research output: Contribution to journalArticle

Springer, Matthew L. ; Hortelano, Gonzalo ; Bouley, Donna M. ; Wong, Jason ; Kraft, Peggy E. ; Blau, Helen M. / Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor. In: Journal of Gene Medicine. 2000 ; Vol. 2, No. 4. pp. 279-288.
@article{4afacbffb2ec4bbba878e56050604c0c,
title = "Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor",
abstract = "Background: We previously demonstrated that intramuscular implantation of primary myoblasts engineered to express vascular endothelial growth factor (VEGF) constitutively resulted in hemangioma formation and the appearance of VEGF in the circulation. To investigate the potential for using allogeneic myoblasts and the effects of delivery of VEGF-expressing myoblasts to non-muscle sites, we have enclosed them in microcapsules that protect allogeneic cells from rejection, yet allow the secretion of proteins produced by the cells. Methods: Encapsulated mouse primary myoblasts that constitutively expressed murine VEGF164, or encapsulated negative control cells, were implanted either subcutaneously or intraperitoneally into mice. Results: Upon subcutaneous implantation, capsules containing VEGF-expressing myoblasts gave rise to large tissue masses at the implantation site that continued to grow and were composed primarily of endothelial and smooth muscle cells directly surrounding the capsules, and macrophages and capillaries further away from the capsules. Similarly, when injected intraperitoneally, VEGF-producing capsules caused significant localized inflammation and angiogenesis within the peritoneum, and ultimately led to fatal intraperitoneal hemorrhage. Notably, however, VEGF was not detected in the plasma of any mice. Conclusions: We conclude that encapsulated primary myoblasts persist and continue to secrete VEGF subcutaneously and intraperitoneally, but that the heparin-binding isoform VEGF164 exerts localized effects at the site of production. VEGF secreted from the capsules attracts endothelial and smooth muscle cells in a macrophage-independent manner. These results, along with our previous results, show that the mode and site of delivery of the same factor by the same engineered myoblasts can lead to markedly different outcomes. Moreover, the results confirm that constitutive delivery of high levels of VEGF is not desirable. In contrast, regulatable expression may lead to efficacious, safe, and localized VEGF delivery by encapsulated allogeneic primary myoblasts that can serve as universal donors.",
keywords = "Angiogenesis, Encapsulation, Gene therapy, Myoblasts, VEGF",
author = "Springer, {Matthew L.} and Gonzalo Hortelano and Bouley, {Donna M.} and Jason Wong and Kraft, {Peggy E.} and Blau, {Helen M.}",
year = "2000",
language = "English",
volume = "2",
pages = "279--288",
journal = "Journal of Gene Medicine",
issn = "1099-498X",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Induction of angiogenesis by implantation of encapsulated primary myoblasts expressing vascular endothelial growth factor

AU - Springer, Matthew L.

AU - Hortelano, Gonzalo

AU - Bouley, Donna M.

AU - Wong, Jason

AU - Kraft, Peggy E.

AU - Blau, Helen M.

PY - 2000

Y1 - 2000

N2 - Background: We previously demonstrated that intramuscular implantation of primary myoblasts engineered to express vascular endothelial growth factor (VEGF) constitutively resulted in hemangioma formation and the appearance of VEGF in the circulation. To investigate the potential for using allogeneic myoblasts and the effects of delivery of VEGF-expressing myoblasts to non-muscle sites, we have enclosed them in microcapsules that protect allogeneic cells from rejection, yet allow the secretion of proteins produced by the cells. Methods: Encapsulated mouse primary myoblasts that constitutively expressed murine VEGF164, or encapsulated negative control cells, were implanted either subcutaneously or intraperitoneally into mice. Results: Upon subcutaneous implantation, capsules containing VEGF-expressing myoblasts gave rise to large tissue masses at the implantation site that continued to grow and were composed primarily of endothelial and smooth muscle cells directly surrounding the capsules, and macrophages and capillaries further away from the capsules. Similarly, when injected intraperitoneally, VEGF-producing capsules caused significant localized inflammation and angiogenesis within the peritoneum, and ultimately led to fatal intraperitoneal hemorrhage. Notably, however, VEGF was not detected in the plasma of any mice. Conclusions: We conclude that encapsulated primary myoblasts persist and continue to secrete VEGF subcutaneously and intraperitoneally, but that the heparin-binding isoform VEGF164 exerts localized effects at the site of production. VEGF secreted from the capsules attracts endothelial and smooth muscle cells in a macrophage-independent manner. These results, along with our previous results, show that the mode and site of delivery of the same factor by the same engineered myoblasts can lead to markedly different outcomes. Moreover, the results confirm that constitutive delivery of high levels of VEGF is not desirable. In contrast, regulatable expression may lead to efficacious, safe, and localized VEGF delivery by encapsulated allogeneic primary myoblasts that can serve as universal donors.

AB - Background: We previously demonstrated that intramuscular implantation of primary myoblasts engineered to express vascular endothelial growth factor (VEGF) constitutively resulted in hemangioma formation and the appearance of VEGF in the circulation. To investigate the potential for using allogeneic myoblasts and the effects of delivery of VEGF-expressing myoblasts to non-muscle sites, we have enclosed them in microcapsules that protect allogeneic cells from rejection, yet allow the secretion of proteins produced by the cells. Methods: Encapsulated mouse primary myoblasts that constitutively expressed murine VEGF164, or encapsulated negative control cells, were implanted either subcutaneously or intraperitoneally into mice. Results: Upon subcutaneous implantation, capsules containing VEGF-expressing myoblasts gave rise to large tissue masses at the implantation site that continued to grow and were composed primarily of endothelial and smooth muscle cells directly surrounding the capsules, and macrophages and capillaries further away from the capsules. Similarly, when injected intraperitoneally, VEGF-producing capsules caused significant localized inflammation and angiogenesis within the peritoneum, and ultimately led to fatal intraperitoneal hemorrhage. Notably, however, VEGF was not detected in the plasma of any mice. Conclusions: We conclude that encapsulated primary myoblasts persist and continue to secrete VEGF subcutaneously and intraperitoneally, but that the heparin-binding isoform VEGF164 exerts localized effects at the site of production. VEGF secreted from the capsules attracts endothelial and smooth muscle cells in a macrophage-independent manner. These results, along with our previous results, show that the mode and site of delivery of the same factor by the same engineered myoblasts can lead to markedly different outcomes. Moreover, the results confirm that constitutive delivery of high levels of VEGF is not desirable. In contrast, regulatable expression may lead to efficacious, safe, and localized VEGF delivery by encapsulated allogeneic primary myoblasts that can serve as universal donors.

KW - Angiogenesis

KW - Encapsulation

KW - Gene therapy

KW - Myoblasts

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0034218552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034218552&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 279

EP - 288

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

SN - 1099-498X

IS - 4

ER -